---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-027974"
form_type: "8-K"
ticker: "KALV"
cik: "0001348911"
company_name: "KalVista Pharmaceuticals, Inc."
filed_at: "2023-06-14T23:59:59+00:00"
generated_at: "2026-06-14T01:03:12.836377+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# KalVista amends CFO employment agreement raising base salary to $565K; updates bylaws for universal proxy rules

## Summary
- CFO Benjamin L. Palleiko's base salary raised to $565,000 (effective May 1, 2023); target bonus increased to 50% of salary.
- Severance: 15 months base salary and COBRA if terminated without cause/for good reason before Change in Control.
- If terminated within 2 years after Change in Control: 21 months base salary, full target bonus, full equity vesting, COBRA.
- Bylaws amended for DGCL updates, universal proxy rules, and exclusive forum (Delaware Chancery Court).

## SEC filing metadata
- accession: 0000950170-23-027974
- form_type: 8-K
- ticker: KALV
- cik: 0001348911
- company_name: KalVista Pharmaceuticals, Inc.
- filed_at: 2023-06-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000095017023027974/0000950170-23-027974-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000095017023027974/kalv-20230608.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-027974
- JSON: https://secwatch.observer/filing/0000950170-23-027974.json
- Plain text: https://secwatch.observer/filing/0000950170-23-027974.txt

## Key facts
- Governance Changes
  KalVista Pharmaceuticals, Inc.: Adopted amended and restated bylaws effective June 14, 2023, incorporating changes related to universal proxy rules, recent DGCL amendments, and other governance updates (effective 2023-06-14).
  - Change: bylaw amendment
  - Effective: 2023-06-14
  source text: On June 14, 2023, in connection with the effectiveness of new Securities and Exchange Commission rules regarding universal proxy cards, certain recent changes to the Delaware General Corporation Law (the “ DGCL ”), and a periodic review of the bylaws of KalVista Pharmaceuticals, Inc. (the “ Company ”), the Company’s board of directors (the “ Board ”) approved and adopted the Company’s amended and restated bylaws (the “ Amended and Restated Bylaws ”), which became immediately effective.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1348911/000095017023027974/0000950170-23-027974-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.